Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio

No abstract is available for this paper.

• Publication year

  2010

• Venue

  EMBO Journal

• Publication date

  2010-10-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/emboj.2010.211PMID 20818335PMCID PMC2957213
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process.

  2010cited by this paper
• Structure–neurotoxicity relationships of amyloid β-protein oligomers

  2009cited by this paper
• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease

  2009cited by this paper
• Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide

  2009cited by this paper
• Faculty Opinions recommendation of Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.

  2009cited by this paper
• Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers

  2009cited by this paper
• The Ratio of Monomeric to Aggregated Forms of Aβ40 and Aβ42 Is an Important Determinant of Amyloid-β Aggregation, Fibrillogenesis, and Toxicity*

  2008cited by this paper
• Frequent amyloid deposition without significant cognitive impairment among the elderly.

  2008cited by this paper
• Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology

  2008cited by this paper
• Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization

  2008cited by this paper
• Stabilization of Neurotoxic Soluble β-Sheet-Rich Conformations of the Alzheimer's Disease Amyloid-β Peptide

  2008cited by this paper
• Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

  2008cited by this paper
• Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide.

  2008cited by this paper
• Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein.

  2007cited by this paper
• Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease.

  2007cited by this paper
• Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease.

  2007cited by this paper
• Lipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice

  2007influential reference
• Abeta40 protects non-toxic Abeta42 monomer from aggregation.

  2007cited by this paper
• Aβ40 Protects Non-toxic Aβ42 Monomer from Aggregation

  2007cited by this paper
• Loss‐of‐function presenilin mutations in Alzheimer disease

  2007cited by this paper
• Aβ40 Inhibits Amyloid Deposition In Vivo

  2007cited by this paper
• Abeta40 inhibits amyloid deposition in vivo.

  2007cited by this paper
• Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease

  2007cited by this paper
• Equimolar Production of Amyloid β-Protein and Amyloid Precursor Protein Intracellular Domain from β-Carboxyl-terminal Fragment by γ-Secretase*

  2006cited by this paper
• Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase.

  2006cited by this paper
• A specific amyloid-beta protein assembly in the brain impairs memory.

  2006cited by this paper
• A specific amyloid-β protein assembly in the brain impairs memory

  2006cited by this paper
• Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms

  2006cited by this paper
• Solution state characterization of amyloid beta-derived diffusible ligands.

  2006cited by this paper
• Solution State Characterization of Amyloid β-Derived Diffusible Ligands

  2006cited by this paper
• Wild-type Presenilin 1 Protects against Alzheimer Disease Mutation-induced Amyloid Pathology*

  2006cited by this paper
• Longer Forms of Amyloid β Protein: Implications for the Mechanism of Intramembrane Cleavage by γ-Secretase

  2005cited by this paper
• Natural oligomers of the amyloid-β protein specifically disrupt cognitive function

  2005cited by this paper
• Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase.

  2005cited by this paper
• Nucleation-Dependent Polymerization Is an Essential Component of Amyloid-Mediated Neuronal Cell Death

  2005cited by this paper
• Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss

  2003cited by this paper
• Biological application of microelectrode arrays in drug discovery and basic research

  2003cited by this paper
• Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of beta-amyloid precursor protein.

  2003cited by this paper
• Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation.

  2003cited by this paper
• Specific Compositions of Amyloid-β Peptides as the Determinant of Toxic β-Aggregation*

  2003cited by this paper
• Co-incorporation of Aβ40 and Aβ42 to form mixed pre-fibrillar aggregates

  2003cited by this paper
• Co-incorporation of A beta 40 and A beta 42 to form mixed pre-fibrillar aggregates.

  2003cited by this paper
• Potential Link between Amyloid β-Protein 42 and C-terminal Fragment γ 49–99 of β-Amyloid Precursor Protein*

  2003cited by this paper
• Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis

  2003cited by this paper
• Neurodegenerative disease: Amyloid pores from pathogenic mutations

  2002cited by this paper
• Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

  2002cited by this paper
• Recent temperature trends in the Antarctic. Authors' reply

  2002cited by this paper
• A cell biological perspective on Alzheimer's disease.

  2002cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Faculty Opinions recommendation of Neurodegenerative disease: amyloid pores from pathogenic mutations.

  2002cited by this paper
• A new approach to neural cell culture for long-term studies.

  2001cited by this paper
• Ultrastructural organization of amyloid fibrils by atomic force microscopy.

  2000cited by this paper
• Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons

  1999cited by this paper
• Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease

  1999cited by this paper
• Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

  1998cited by this paper
• Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins.

  1997cited by this paper
• Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice

  1997cited by this paper
• Glutamine Synthetase‐Induced Enhancement of β‐Amyloid Peptide Aβ(1–40) Neurotoxicity Accompanied by Abrogation of Fibril Formation and Aβ Fragmentation

  1996cited by this paper
• Glutamine synthetase-induced enhancement of beta-amyloid peptide A beta (1-40) neurotoxicity accompanied by abrogation of fibril formation and A beta fragmentation.

  1996cited by this paper
• Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

  1996influential reference
• Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain.

  1996cited by this paper
• Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.

  1996cited by this paper
• Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1

  1996cited by this paper
• Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43).

  1996cited by this paper
• Amyloid β protein (Aβ) deposition in chromosome 14–linked Alzheimer's disease: Predominance of Aβ42(43)

  1996cited by this paper
• Amino-terminal Deletions Enhance Aggregation of β-Amyloid Peptides in Vitro(*)

  1995cited by this paper
• Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro.

  1995cited by this paper
• An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.

  1994cited by this paper
• Determination of soluble and membrane protein structure by Fourier transform infrared spectroscopy. I. Assignments and model compounds.

  1994cited by this paper
• Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths.

  1994cited by this paper
• Determination of soluble and membrane protein structure by Fourier transform infrared spectroscopy. II. Experimental aspects, side chain structure, and H/D exchange.

  1994cited by this paper
• Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?

  1993cited by this paper
• Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide.

  1993cited by this paper
• Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide

  1993cited by this paper
• Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

  1991cited by this paper
• Recording action potentials from cultured neurons with extracellular microcircuit electrodes.

  1980cited by this paper
• Infrared spectra and resonance interaction of amide-I vibration of the paraellel-chain pleated sheets.

  1976cited by this paper
• Infrared spectra and resonance interaction of amide‐I vibration of the antiparallel‐chain pleated sheet

  1976cited by this paper

• The Icelandic Mutation in the Murine APP Gene, mAPPA673T, on Amyloid-β Plaque Burden in the 5×FAD Alzheimer Model.

  2026cites this paper
• MiR-34a deficiency enhances nucleic acid sensing and type I IFN signaling in a mouse model of Alzheimer’s disease

  2026cites this paper
• Elucidation of Molecular Mechanisms of Lipid-Altered Cytotoxicity of TDP-43 Fibrils.

  2026cites this paper
• Anti-CLEC7A nanobody in situ engineering promotes amyloid-β oligomers clearance by CAR-microglia to alleviate Alzheimer's disease pathology in mice.

  2026cites this paper
• A novel presenilin 1 nucleotide mutation (M139I) and its pathological function in a Chinese family with early-onset Alzheimer's disease.

  2026cites this paper
• The Role of Thionine on Amyloid Precursor Protein Processing in N2a-APPSwe Cells

  2025cites this paper
• Decoding the Relationship between Alzheimer's Disease and Type-2 Diabetes via the Protein Aggregation Prism.

  2025cites this paper
• Protective ApoE variants support neuronal function by effluxing oxidized phospholipids.

  2025cites this paper
• Aggregation shifts amyloid-β peptides from synaptogenic to synaptotoxic

  2025cites this paper
• Comparing high and low amyloid producers in Alzheimer's disease: An in-depth analysis.

  2025cites this paper
• Simulation study of solvent effect on competitive degradation of aggregation of homo- and hetero- amyloid-β dimers

  2025cites this paper
• Aducanumab binds high molecular weight soluble Aβ oligomers and restores intracellular calcium levels

  2025cites this paper
• Amyloid‐β Seeds in Alzheimer's Disease: Research Challenges and Implications

  2025cites this paper
• Functions of the basal lamina and ApoE in cerebral amyloid angiopathy

  2025cites this paper
• Linking higher amyloid beta 1‐38 (Aβ(1‐38)) levels to reduced Alzheimer's disease progression risk

  2025cites this paper
• Bone marrow-derived myeloid cells drive neuroinflammation in Alzheimer's disease: Insights from the FAD4T mouse model

  2025cites this paper
• Direct Observation of Amyloid-β 42 Oligomer, Fibril, and Amorphous Aggregate Growth and Dissolution at Biomimetic Concentrations.

  2025cites this paper
• Streamlined E. coli expression and purification of amyloid beta peptides via inclusion body formation and fluorescence monitoring.

  2025cites this paper
• P-glycoprotein and Alzheimer’s Disease: Threats and Opportunities

  2025cites this paper
• The tau isoform 1N4R confers vulnerability of MAPT knockout human iPSC‐derived neurons to amyloid beta and phosphorylated tau‐induced neuronal dysfunction

  2025cites this paper
• Protective ApoE variants support neuronal function by extracting peroxidated lipids

  2025cites this paper
• Proteome-Based Biomarkers for Alzheimer’s Disease: Old Acquisitions and Innovative Proposals

  2025cites this paper
• Biophysical insights into the molecular mechanisms of beta amyloid aggregation and its toxic effects in Alzheimer’s disease

  2025cites this paper
• Membrane Charge Drives the Aggregation of TDP-43 Pathological Fragments

  2025cites this paper
• Molecular Determinants of Protein Pathogenicity at the Single‐Aggregate Level

  2025cites this paper
• Leveraging heterocycle-fused 1,4-benzoquinone to design chemical modulators for both metal-free and metal-bound amyloid-β

  2025cites this paper
• Spectral Heterogeneity of Thioflavin T Binding to Aβ42:Aβ40 Mixed Fibrils: Implications for Alzheimer’s Disease Screening

  2025cites this paper
• RAGE-Mediated Effects of Formaldehyde in Alzheimer’s Disease

  2025cites this paper
• Designing novel peptides with amyloid-β binding and clearance potential using BiLSTM and molecular dynamics

  2025cites this paper
• The Icelandic mutation APPA673T on amyloid-β plaque burden in the 5xFAD Alzheimer model

  2025cites this paper
• Aβ-42 sidechain deamidation at Q15 or N27 modulates protein aggregation and alters microglial cytokines and CD68

  2025cites this paper
• MiR-34a deficiency enhances nucleic acid sensing and type I IFN signaling in a mouse model of Alzheimer’s disease

  2025cites this paper
• Distinctive contribution of two additional residues in protein aggregation of Aβ42 and Aβ40 isoforms

  2024cites this paper
• Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease

  2024cites this paper
• Zinc utilization by microglia in Alzheimer’s disease

  2024cites this paper
• Xenografted human microglia display diverse transcriptomic states in response to Alzheimer’s disease-related amyloid-β pathology

  2024cites this paper
• Histidine Protonation Behaviors on Structural Properties and Aggregation Properties of Aβ(1-42) Mature Fibril: Approaching by Edge Effects.

  2024cites this paper
• Monoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease

  2024cites this paper
• Integrating rare pathogenic variant prioritization with gene‐based association analysis to identify novel genes and relevant multimodal traits for Alzheimer's disease

  2024cites this paper
• Exploring Heparan Sulfate Proteoglycans as Mediators of Human Mesenchymal Stem Cell Neurogenesis

  2024cites this paper
• Latest advances in mechanisms of epileptic activity in Alzheimer’s disease and dementia with Lewy Bodies

  2024cites this paper
• Mechanism interpretation of Guhan Yangshengjing for protection against Alzheimer's disease by network pharmacology and molecular docking.

  2024cites this paper
• Presenilin: A Multi-Functional Molecule in the Pathogenesis of Alzheimer’s Disease and Other Neurodegenerative Diseases

  2024cites this paper
• A critical appraisal of geroprotective activities of flavonoids in terms of their bio-accessibility and polypharmacology.

  2024cites this paper
• Copper(II) Can Kinetically Trap Arctic and Italian Amyloid-β40 as Toxic Oligomers, Mimicking Cu(II) Binding to Wild-Type Amyloid-β42: Implications for Familial Alzheimer’s Disease

  2024cites this paper
• Genomic stress and impaired DNA repair in Alzheimer disease.

  2024cites this paper
• Anatomical, Physiological, and Pathological Changes in Different Parts of the Brain in Alzheimer's Disease

  2024cites this paper
• The pathogenicity of PSEN2 variants is tied to Aβ production and homology to PSEN1

  2024cites this paper
• From defense to disease: IFITM3 in immunity and Alzheimer's disease

  2024cites this paper
• MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non‐clinical species and Alzheimer's disease patients

  2024cites this paper
• Single-Molecule Characterization of Heterogeneous Oligomer Formation during Co-Aggregation of 40- and 42-Residue Amyloid-β.

  2024cites this paper
• Amyloid pathology and cognitive impairment in hAβ-KI and APPSAA-KI mouse models of Alzheimer's disease.

  2024cites this paper
• γ-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).

  2024cites this paper
• Repurposing doxycycline for Alzheimer's treatment: Challenges from a nano-based drug delivery perspective

  2024cites this paper
• The Aβ42:Aβ40 ratio modulates aggregation in beta-amyloid oligomers and drives metabolic changes and cellular dysfunction

  2024cites this paper
• Amyloid beta 1‐40 and 1‐42 fibril ratios and maturation level cause conformational differences with minimal impact on autophagy and cytotoxicity

  2024influential citation
• E22G Aβ40 fibril structure and kinetics illuminate how Aβ40 rather than Aβ42 triggers familial Alzheimer’s

  2024cites this paper
• Newer modalities in the management of Alzheimer's dementia along with the role of aducanumab and lecanemab in the treatment of its refractory cases.

  2023cites this paper
• Deciphering mechanisms of action of ACE inhibitors in neurodegeneration using Drosophila models of Alzheimer’s disease

  2023cites this paper
• Hesperidin methylchalcone (HMC) hinders amyloid-β induced Alzheimer's disease by attenuating cholinesterase activity, macromolecular damages, oxidative stress and apoptosis via regulating NF-κB and Nrf2/HO-1 pathways.

  2023cites this paper
• Presenilin 1 deficiency impairs Aβ42-to-Aβ40- and angiotensin-converting activities of ACE

  2023influential citation
• Imaging Amyloid‐β Membrane Interactions: Ion‐Channel Pores and Lipid‐Bilayer Permeability in Alzheimer's Disease

  2023cites this paper
• Dissecting the Molecular Mechanisms of the Co-Aggregation of Aβ40 and Aβ42 Peptides: A REMD Simulation Study.

  2023cites this paper
• Prospective analysis of plasma amyloid beta and postoperative delirium in the Interventions for Postoperative Delirium: Biomarker-3 study.

  2023cites this paper
• The stability and dynamics of the Aβ40/Aβ42 interlaced mixed fibrils

  2023cites this paper
• Predictive network analysis identifies JMJD6 and other potential key drivers in Alzheimer’s disease

  2023cites this paper
• A Biomimic Nanobullet with Ameliorative Inflammatory Microenvironment for Alzheimer's Disease Treatments

  2023cites this paper
• Aggregation Dynamics Characteristics of Seven Different Aβ Oligomeric Isoforms-Dependence on the Interfacial Interaction.

  2023cites this paper
• Curcumin-derived carbon quantum dots: Dual actions in mitigating tau hyperphosphorylation and amyloid beta aggregation.

  2023cites this paper
• APP‐C31: An Intracellular Promoter of Both Metal‐Free and Metal‐Bound Amyloid‐β40 Aggregation and Toxicity in Alzheimer's Disease

  2023cites this paper
• Conformational Properties of Aβ Peptide Oligomers in Aqueous Ionic Liquid Solution: Insights from Molecular Simulation Studies.

  2023cites this paper
• Potentially Pathogenic SORL1 Mutations Observed in Autosomal-Dominant Cases of Alzheimer’s Disease Do Not Modulate APP Physiopathological Processing

  2023cites this paper
• Imaging Amyloid‐β Membrane Interactions: Ion‐Channel Pores and Lipid‐Bilayer Permeability in Alzheimer's Disease

  2023cites this paper
• Development of an accelerated cellular model for early changes in Alzheimer’s disease

  2023cites this paper
• Influence of CurQfen®-curcumin on cognitive impairment: a randomized, double-blinded, placebo-controlled, 3-arm, 3-sequence comparative study

  2023cites this paper
• Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study

  2023cites this paper
• Polyphenols’ Impact on Selected Biomarkers of Brain Aging in Healthy Middle-Aged and Elderly Subjects: A Review of Clinical Trials

  2023cites this paper
• The intracerebral injection of Aβ1-42 oligomers does not invariably alter seizure susceptibility in mice

  2023cites this paper
• The link between Alzheimer disease and metabolic syndrome: A mutual relationship and long rigorous investigation.

  2023cites this paper
• Presenilin homologues influence substrate binding and processing by γ-secretase: a molecular simulation study

  2023cites this paper
• Biological Effects and Mechanisms of Taurine in Various Therapeutics.

  2023cites this paper
• Secreted endogenous macrosomes reduce Aβ burden and ameliorate Alzheimer’s disease

  2023cites this paper
• Hippocampal injections of soluble amyloid-beta oligomers alter electroencephalographic activity during wake and slow-wave sleep in rats

  2023cites this paper
• Therapeutic Potential of Targeting Mitochondria for Alzheimer’s Disease Treatment

  2022cites this paper
• Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer’s disease

  2022cites this paper
• Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts

  2022cites this paper
• Edaravone Attenuates Aβ 1-42-Induced Inflammatory Damage and Ferroptosis in HT22 Cells

  2022cites this paper
• Effects of Combining Biofactors on Bioenergetic Parameters, Aβ Levels and Survival in Alzheimer Model Organisms

  2022cites this paper
• Enhancing the Amyloid-β Anti-Aggregation Properties of Curcumin via Arene-Ruthenium(II) Derivatization

  2022cites this paper
• A multi-pronged human microglia response to Alzheimer’s disease Aβ pathology

  2022cites this paper
• Amyloid-β aggregates induced by β-cholesteryl glucose-embedded liposomes.

  2022cites this paper
• In-Depth Characterization of Endo-Lysosomal Aβ in Intact Neurons

  2022cites this paper
• Toluidine blue O attenuates tau phosphorylation in N2a-APPSwe cells.

  2022cites this paper
• Effects of ischemia-hypoperfusion on neuro-vascular units in dual transgenic mice with Alzheimer's disease.

  2022cites this paper
• Amyloids on Membrane Interfaces: Implications for Neurodegeneration

  2022cites this paper
• Sticker-and-spacer model for amyloid beta condensation and fibrillation

  2022cites this paper
• Scan-Find-Scan-Model: Discrete Site-Targeted Suppressor Design Strategy for Amyloid-β.

  2022cites this paper
• Taylor Dispersion Analysis and Atomic Force Microscopy Provide a Quantitative Insight into the Aggregation Kinetics of Aβ (1-40)/Aβ (1-42) Amyloid Peptide Mixtures.

  2022cites this paper
• Relationship between Cognitive Dysfunction and Age-Related Variability in Oxidative Markers in Isolated Mitochondria of Alzheimer’s Disease Transgenic Mouse Brains

  2022cites this paper
• β‐Lactolin improves mitochondrial function in Aβ‐treated mouse hippocampal neuronal cell line and a human iPSC‐derived neuronal cell model of Alzheimer's disease

  2022cites this paper